AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 32 min read$MAZENeutralLow

Bernstein Harold sold $42K of MAZE

Bernstein Harold (President, R&D & CMO) sold 1,600 shares of Maze Therapeutics, Inc. (MAZE) at $26.36 on 2026-06-01 under a Rule 10b5-1 trading plan.

Bernstein HaroldJune 3, 2026
AI analysis
Relevance
6/10
Novelty
6/10
Actionability
Low
Sentiment · $MAZE
Neutral
Timing
Filed June 3; sale executed June 1
Market alignment
Neutral—insider sale without clear new fundamental catalyst
Why this matters for $MAZE

Insider selling disclosed via Form 4; likely low fundamental signal given 10b5-1 pre-arranged nature.

Relevance context

SEC Form 4 shows MAZE President of R&D & CMO sold 1,600 shares in an open-market transaction under a 10b5-1 plan.

Price-impact prediction

Limited near-term impact; any reaction is likely muted and short-lived.

Background

This is an SEC Form 4 insider transaction disclosure for Maze Therapeutics, Inc.

Why it matters

The disclosure updates the insider activity record but does not introduce new clinical, regulatory, or financial information.

Market relevance

Traders may briefly reassess sentiment around MAZE based on insider activity, but the 10b5-1 structure typically limits signal strength.

Market effects

Sector

Minimal; single-company insider transaction with no stated operational/regulatory catalyst.

Regional

None indicated.

Global

None indicated.

Alternative perspectives

Contrarian view

Even with 10b5-1, repeated insider selling can coincide with perceived risk; traders may watch for follow-on sales or lack of buys.

Overlooked factors

The filing doesn’t reveal reasons for sale, tax planning, or diversification; size is modest and post-transaction holdings are zero, but that alone isn’t proof of negative outlook.

Key entities

  • issuer
    Maze Therapeutics, Inc.

    Subject of the Form 4 insider sale by its President, R&D & CMO.

  • insider
    Harold Bernstein

    Officer (President, R&D & CMO) who sold shares under a Rule 10b5-1 plan.

Read at source← All news

Related articles

APR 8
$MAZEMed

San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial

H.C. Wainwright reiterated its Buy rating and $110 price target for Maze Therapeutics (MAZE) after KOL calls validated the HORIZON Phase 2 dataset, confirming the drug's efficacy in different patient cohorts. The data provides a clear path to pivotal trials, suggesting separate non-diabetic and diabetic arms with distinct endpoints. Analysts also noted the potential long-term advantages of MZE829 over competitors and anticipate that upcoming data from Vertex Pharmaceuticals' AMPLIFIED trial could further validate the APOL1 inhibition mechanism.

Streetwise Reports4 min
JAN 1
$MAZELow

Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 5,000 Shares of Stock

Maze Therapeutics (NASDAQ:MAZE) SVP Amy Bachrodt recently sold 5,000 shares of company stock in a transaction on December 30th for $200,400, following an earlier sale of 10,000 shares on December 29th for $405,800. After these sales, Bachrodt's direct ownership in the company decreased by 27.83% to 12,965 shares. The stock has seen significant price movement and positive analyst ratings, with an average "Buy" rating and a target price of $43.38 from Wall Street analysts.

MarketBeat2 min